Data from murine models have shown an interaction between ASXL1, RUNX1, EZH2, TP53 and BCL-2 expression, suggesting that BCL-2 inhibition might fail to kill progenitors in MDS that harbor any of these mutations (226, 227). The gene discussed is TP53; the disease is myelodysplastic syndrome.